Resverlogix Corp. (OTC:RVXCF)
Industry: Healthcare

OFF LIST - 761 consecutive market days: OFF LIST as of 05/28/2013 Through 11/14/2016

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.

Current Quote*
Last: $0.030
Change: 0.000
Book: $Unk
Volume: 4,000

As Of: 07/11 16:15 ET
*Quotes delayed by 20min.

BuyIns.Net Alerts for Symbol RVXCF

  • No BuyIns.Net Alerts Available for RVXCF

Graphs for RVXCF


3 Month Graph


6 Month Graph


1 Year Graph